publication date: Nov. 2, 2018

NCI Trials

NCI Trials for November

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

 

Phase I NRG-GY017

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer

NRG Oncology

Mayadev, Jyoti S.

(858) 822-7499

 

Phase I PBTC-049

A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors

Pediatric Brain Tumor Consortium

Salloum, Ralph

(513) 636-1281

 

Phase II 10191

A Phase 2 Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

Dana-Farber – Harvard Cancer Center LAO

Choudhury, Atish Dipankar

(617) 632-6328

 

Phase II 10193

Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Mayo Clinic Cancer Center LAO

Bennani, Nabila Nora

(507) 284-2511

 

Phase II ACNS1721

A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations

Children’s Oncology Group

Karajannis, Matthias A.

(212) 639-3171

 

Phase III A221702

ARM: Axillary Reverse Mapping – A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and without Axillary Reverse Mapping

Alliance for Clinical Trials in Oncology

Klimberg, V. Suzanne

(501) 680-0779

 

Phase III EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

ECOG-ACRIN Cancer Research Group

Gastman, Brian R.

(216)-444-6901

 

Phase III S1714

A Prospective Observational Cohort Study to develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

SWOG

Trivedi, Meghna S.

(212) 305-1945

 

Phase Other ARST18B3-Q

Development of Circulating Tumor DNA Assays for Embryonal Rhabdomyosarcoma

Children’s Oncology Group

Crompton, Brian

(617) 632-4468

 

Phase Other WF-1803CD

Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices

Wake Forest NCORP Research Base

Nightingale, Chandylen

(336) 713-1432

Copyright (c) 2018 The Cancer Letter Inc.